As innovations in combinatorial chemistry and high throughput screening continue to drive small molecule pipeline growth, the number of poorly soluble molecules that require advanced formulation technologies to enhance bioavailability reaches new heights1. Identifying the appropriate technology to overcome bioavailability challenges in early development is essential to avoiding costly and lengthy development programs.

In a recent industry survey seeking to discover the challenges in developing oral dosage forms, respondents shared their top motivations and hurdles when selecting bioavailability enhancement technologies.

Join this webcast as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

Key Learnings:

  • Gain industry perspectives on how drug developers are approaching bioavailability, key challenges and the most preferred formulation strategies
  • Understand physiological barriers to oral absorption
  • Learn more about traditional approaches to improve bioavailability
  • Discover advanced formulation techniques for improving bioavailability

References:
1. Drug Delivery Technologies Market Forecast 2019-2029, VISIONGAIN Feb 2019

Featured Speakers

Mark Saunders

Consultant
P2C Pharma

Mark obtained his degree in Biomedicinal Chemistry from The University of Exeter and gain his PhD in Pharmaceutical Drug Delivery from The London School of Pharmacy (now part of University College London). Mark has worked in the CRO field for 20 years, most recently as the CEO and Founder of Kuecept Ltd, a specialist CRO dedicated to early-stage drug pre/formulation for compounds that exhibit complex bioavailability barriers. After selling the company in 2016, Mark established P2C Pharma, a consultancy company offering support to companies in the early drug development stages.

Brent Moody

Principal Scientist, Business Development
Catalent Pharma Solutions

Brent Moody is a Principal Scientist at Catalent Pharma Solutions. He has over 22 years of experience in drug product development and GMP manufacturing operations. Brent’s background includes preclinical and clinical drug product strategy, formulation and analytical development for small molecules and peptides, project leadership, and laboratory supervision. Brent joined Catalent in 2016 through the acquisition of Pharmatek Laboratories, a California-based CDMO focused on solubility-enhancement for early-stage drug candidates where he served as a Senior Scientist and Technical Business Director. He holds a bachelor’s degree in Chemistry from East Carolina University.

Nick Taylor

Editor
FiercePharma

Nick Taylor is a writer with more than 10 years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including FierceBiotech and Nature's BioPharma Dealmakers.

NOW AVAILABLE ON-DEMAND

Register now for this webinar